文献速递临床试验与 GCP

氢化可的松对重症COVID-19患者21天死亡率或呼吸支持的影响:一项随机临床试验

Effect of Hydrocortisone on 21-Day Mortality or Respiratory Support Among Critically Ill Patients With COVID-19: A Randomized Clinical Trial.
PubMed 文献 · JAMA · 2020-01-01

这项在法国开展的多中心随机双盲序贯试验,纳入149例COVID-19相关急性呼吸衰竭的ICU患者,比较低剂量氢化可的松与安慰剂。研究因提前终止可能把握度不足。

要点

  • 低剂量氢化可的松未显著降低21天治疗失败率。
  • 治疗失败定义为死亡或持续依赖机械通气或高流量氧疗。
  • 研究提前终止,可能不足以检出有临床意义的差异。

核心结论

  • 在重症COVID-19合并急性呼吸衰竭患者中,与安慰剂相比,低剂量氢化可的松未显著减少第21天治疗失败。

研究设计与样本

  • 多中心随机双盲序贯试验,在法国开展,计划每50例进行期中分析。
  • 计划入组290例,实际纳入149例后因数据与安全监察委员会建议提前终止。
  • 患者为2020年3月7日至6月1日因COVID-19相关急性呼吸衰竭入住ICU者,末次随访2020年6月29日。
  • 随机分组:低剂量氢化可的松组76例,安慰剂组73例。

主要发现

  • 149例患者平均年龄62.2岁,女性占30.2%,81.2%接受机械通气。
  • 4项预设次要结局均未显示显著差异。
  • 未发生与研究治疗相关的严重不良事件。

临床怎么用

  • 对于重症COVID-19急性呼吸衰竭患者,低剂量氢化可的松不应仅基于本研究结果作为常规推荐。

局限性

  • 研究提前终止,可能把握度不足,无法检出统计学和临床重要的差异。
  • 实际样本量(149例)低于计划样本量(290例)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Coronavirus disease 2019 (COVID-19) is associated with severe lung damage. Corticosteroids are a possible therapeutic option. OBJECTIVE: To determine the effect of hydrocortisone on treatment failure on day 21 in critically ill patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and acute respiratory failure. DESIGN, SETTING, AND PARTICIPANTS: Multicenter randomized double-blind sequential trial conducted in France, with interim analyses planned every 50 patients. Patients admitted to the intensive care unit (ICU) for COVID-19-related acute respiratory failure were enrolled from March 7 to June 1, 2020, with last follow-up on June 29, 2020. The study intended to enroll 290 patients but was stopped early following the recommendation of the data and safety monitoring board. INTERVENTIONS: Patients were randomized to receive low-dose hydrocortisone (n = 76) or placebo (n = 73). MAIN OUTCOMES AND MEASURES: The primary outcome, treatment failure on day 21, was defined as death or persistent dependency on mechanical ventilation or high-flow oxygen therapy. Prespecified secondary outcomes included the need for tracheal intubation (among patients not intubated at baseline); cumulative incidences (until day 21) of prone position sessions, extracorporeal membrane oxygenation, and inhaled nitric oxide; Pao2:Fio2 ratio measured daily from day 1 to day 7, then on days 14 and 21; and the proportion of patients with secondary infections during their ICU stay. RESULTS: The study was stopped after 149 patients (mean age, 62.2 years; 30.2% women; 81.2% mechanically ventilated) were enrolled. One hundred forty-eight patients (99.3%) completed the study, and there were 69 treatment failure events, including 11 deaths in the hydrocortisone group and 20 deaths in the placebo group. The primary outcome, treatment failure on day 21, occurred in 32 of 76 patients (42.1%) in the hydrocortisone group compared with 37 of 73 (50.7%) in the placebo group (difference of proportions, -8.6% [95.48% CI, -24.9% to 7.7%]; P = .29). Of the 4 prespecified secondary outcomes, none showed a significant difference. No serious adverse events were related to the study treatment. CONCLUSIONS AND RELEVANCE: In this study of critically ill patients with COVID-19 and acute respiratory failure, low-dose hydrocortisone, compared with placebo, did not significantly reduce treatment failure (defined as death or persistent respiratory support) at day 21. However, the study was stopped early and likely was underpowered to find a statistically and clinically important difference in the primary outcome. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02517489.

来源:JAMA,查看原文。版权归原作者所有。

引用

  1. Dequin PF, Heming N, Meziani F, et al. Effect of Hydrocortisone on 21-Day Mortality or Respiratory Support Among Critically Ill Patients With COVID-19: A Randomized Clinical Trial. JAMA. 2020. PMID: 32876689. doi:10.1001/jama.2020.16761

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。